26th Jul 2005 07:00
Sinclair Pharma PLC26 July 2005 SINCLAIR PHARMA PLC Three New Sales and Marketing Agreements: SebclairTM in US, XclairTM and SalinumTM in Greece Godalming UK, 26 July, 2005: Sinclair Pharma plc ("Sinclair" or the "Company")(SPH.L), the specialty pharmaceutical company, today announces the signing ofthree new sales and marketing agreements. In the US, Sinclair has licensedSebclairTM, a treatment for seborrheic dermatitis ("SD"), to Chester ValleyPharmaceuticals ("CVP"), and in Greece Sinclair has licensed two products toAnabiosis Ltd.; XclairTM, its product for the treatment of radiation dermatitis,and SalinumTM, a saliva replacement product for the treatment of dry mouthsyndrome. US Chester Valley Pharmaceuticals ("CVP"), Sinclair's US licensee for Atopiclair(R), the first prescription medical device authorised by the US FDA to relievethe symptoms of atopic dermatitis ("AD") and allergic contact dermatitis ("ACD"), has now licensed SebclairTM for seborrheic dermatitis in the US. The dealincludes upfront and milestone payments of approaching US $4 million androyalties on sales over the life of the 20 year agreement. Sinclair has filed for a 510(k) registration with the US FDA and, subject toapproval, the Company would expect the product to be launched in 2006. Seborrheic dermatitis is a common skin condition that affects an estimated 3-5%*of the US population. On average, men are more prone to having SD than women.The disease is also more common among adults around 40 years of age. The USethical market for SD reached a value of US$256.0 million in 2003, up fromUS$227.4 million in 1999, showing an increase of 12.6% over the review period. Greece Sinclair has appointed Anabiosis Greece ("Anabiosis") as exclusive sales andmarketing partner in Greece for the Company's products XclairTM, a treatment forradiation dermatitis, a common side effect of radiotherapy, and SalinumTM, asaliva replacement product for the treatment of dry mouth syndrome,("xerostomia") where the salivary glands are able to produce little or nosaliva. Anabiosis is fast-growing, private pharmaceutical sales and marketing companyfounded in 2001 by former big pharma executives. The company has three businesssections: Pharma distribution, business consulting and communication solutionsfor the pharmaceutical industry. Their current collaborations include Abbottand Prostrakan. The company was originally established to commercialise NCE andbranded generics and now also in-licenses late stage development projects. Dr Michael Flynn, CEO of Sinclair, said: "We are very pleased to have expandedour relationship with CVP, with its strong management team which has a very goodtrack record of commercialising dermatology products in the US. The appointmentof Anabiosis for XclairTM and SalinumTM in Greece, underpins our strategy oflicensing our products to companies whom we believe are well placed to promoteand sell our products." Robert Moccia, CEO of CVP, stated: "CVP is extremely pleased to continue andexpand its existing collaboration with Sinclair and to add SebclairTM to ourportfolio of derma products. AtopiclairTM is an innovative product which webelieve has significant potential in the US. Similarly, with a total SD marketin the US of over US$200 million, we believe that Sebclair also has significantpotential in this market." * Euromonitor Report in November 2004 Enquiries: Sinclair Pharma plcDr Michael Flynn, CEO Tel: 01483 426 6444John Barrington-Carver (Corporate PR) Tel: 07831 655 630 Financial DynamicsBen Atwell / Lucy Briggs Tel: 0207 831 3113 Notes to editors: Sinclair Pharma plc based in Godalming in the UK, is quoted on the AlternativeInvestment Market (AIM) on the London Stock Exchange and has focused on theacquisition and development of niche patented pharmaceutical products in thefields of oral health, oncology support and dermatology, and bringing them tothe international market place via out-licensing partners. The Company combinesproduct evaluation, product development, regulatory and business developmentexpertise to add value to its acquired and in-house developed products. A keyelement of the Sinclair business model is to minimise risk and exposure byavoiding involvement in lengthy R&D programmes and rapidly achieving globaldistribution through a network of marketing partners. The Company has alreadylicensed its products for distribution in over 40 countries around the world.www.sinclairpharma.com SebclairTM Market Additional Info Major product innovations in the prescriptions (Rx) market led to a value growthof 13% for that sector in the scalp market and 12% growth in the skin market forSD. Scalp Rx products reached a value of US$99.2 million in 2003, representing69.7% of the total market for seborrheic dermatitis, while Skin Rx productsreached a value of US$111.6 million or 98.1% market share from the total US SDmarket. Skin products make up a more significant proportion. Chester Valley Pharmaceuticals is a specialty dermatology company, headed by twohighly experienced and respected pharma executives in dermatology each with asignificant track record in commercialising dermatology products. Robert J.Moccia, Chief Executive Officer of CVP, is the former President of BioglanPharmaceuticals, a specialty dermatology company that was recently sold toBradley Pharmaceuticals for approximately $183 million. As President ofBioglan, he grew the organisation to nearly $60 million in net revenue in lessthan five years. Prior to Bioglan, Mr. Moccia was the Director of WorldwideBusiness and Market Development with Dermik Laboratories, the dermatology unitof Aventis Pharma AG. Xavier Yon, Chairman of CVP, was until recently ChiefExecutive Officer of Galderma, the world's leading dermatology company. AtGalderma he was responsible for building a global organization with worldwidesales in excess of $US 800 million. CVP was formed as a result of a partnershipbetween Moccia, Yon, and GTCR Golder Rauner, LLC (GTCR), one of the leadingprivate equity firms in the US. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma